The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 3 , Pages 505-513 , September 2010

Epithelial to mesenchymal transition: The doorway to metastasis in human lung cancers

Received 28 September 2009 ,Revised 10 January 2010 ,Accepted 1 February 2010.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non–small cell lung cancer. N Engl J Med. 2006;355:2542–2550Erratum in: N Engl J Med. 2007;356:318.
  3. Joy AA, Butts CA. Extending outcomes: epidermal growth factor receptor–targeted monoclonal antibodies in non–small cell lung cancer. Clin Lung Cancer. 2009;1010(Suppl. 1):S24–S29
  4. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells—an integrated concept of malignant tumor progression. Nat Rev Cancer. 2005;5:744–749
  5. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796:75–90
  6. Thiery J. Epithelial-mesenchymal transition in development and pathogenesis. Curr Opin Cell Biol. 2003;15:740–746
  7. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumor ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127–132
  8. Bruyere F, Namdarian B, Corcoran NM, Pedersen J, Ockrim J, Voelzke BB, et al. Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers. Urol Oncol. Epub 2009 Jan 20.
  9. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, et al. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non–small cell lung cancer. Clin Cancer Res. 2008;14:7430–7437
  10. Shih J. Transcription repressor slug promotes carcinoma and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res. 2005;11:8070–8078
  11. Kim MA, Lee HS, Lee HE, Kim JH, Yang HK, Kim WH. Prognostic importance of epithelial-mesenchymal-related protein expression in gastric carcinoma. Histopathology. 2009;54:442–451
  12. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69:5820–5828
  13. Haddad Y, Choi W, McConkey DJ. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epithelial growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res. 2009;15:532–542
  14. Prall F, Nizze H, Barten M. Tumor budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology. 2005;47:17–24
  15. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993;53:1696–1701
  16. Guarino M, Rubino B, Ballabia G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39:305–318
  17. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153:333–339
  18. Nelson WJ, Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science. 2004;303:1483–1487
  19. Connacci-Sorrell M, Simcha I, Ben-Yedidia T, Blechman J, Savagner P, Ben-Ze'ev A, et al. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of β-catenin signaling, Slug, and MAPK. J Cell Biol. 2003;163:847–857
  20. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, et al. Cadherin switching in human prostate cancer progression. Cancer Res. 2000;60:3650–3654
  21. Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell. 2002;2:301–313
  22. Schmidmaier R, Baumann P. Anti-adhesion evolves to a promising therapeutic concept in oncology. Curr Med Chem. 2008;15:978–990
  23. Moreno-Bueno G, Cubillo E, Sarrió D, Peinado H, Rodríguez-Pinilla SM, et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res. 2006;66:9543–9556
  24. Goede V, Brogelli L, Ziche M, Augustin HG. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer. 1999;82:765–770
  25. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-β1 level correlates with angiogenesis tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001;91:964–971
  26. Nawshad A, Lagamba D, Polad A, Hay ED. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs. 2005;179:11–23
  27. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M, et al. Transforming growth factor–β receptor inhibition enhances adenoviral infectability of carcinoma cells via upregulation of Coxsackie and adenovirus receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res. 2006;66:1648–1657
  28. Yu L, Hebert MD, Zhang YE. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002;21:3749–3759
  29. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. Transforming factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependant mechanism. Mol Biol Cell. 2001;12:27–36
  30. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009;28(33):2940–2947
  31. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103:642–646
  32. Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G, et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 2009;18:215–222
  33. Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst. 2007;99:1257–1269
  34. Duryuginia EI, Quigley JP. Matrix metalloproteinase and tumor metastasis. Cancer Metastasis. 2006;25:9–34
  35. Buccione R, Orth JD, McNiven MA. Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nature Rev Mol Cell Biol. 2004;5:647–657
  36. Mandal S, Johnson KR, Wheelock MJ. TGF-β induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways. Exp Cell Res. 2008;314:3478–3493
  37. Basbaum CB, Werb Z. Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol. 1996;8:731–738
  38. Chen WT. Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. J Exp Zool. 1989;251:167–185
  39. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Letter. 2003;194:1–11
  40. Ueda J, Kajita M, Suenaga N, Jugii K, Seika M. Sequence–specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene. 2003;22:8716–8722
  41. Sato H, Takino Y, Okada J, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature. 1994;370:61–65
  42. Hofmann UB, Eggert AA, Blass K, Brocker EB, Becker JC. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res. 2003;63:8221–8225
  43. Takkunen M, Hukkanen M, Liljeström M, Grenman R, Virtanen I. Podosome-like structures of non-invasive carcinoma cells are replaced in epithelial-mesenchymal transition by actin comet-embedded invadopodia. J Cell Mol Med. Epub 2009 Jul 28.
  44. Jung A, Schrauder M, Oswald U, Knoll C, Sellberg P, Palmqvist R, et al. The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear β-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol. 2001;159:1613–1617
  45. Hu CT, Wu JR, Cheng CC, Cheng CC, Wu WS. The transcriptional factor Snail simultaneously triggers cell cycle arrest and migration of human hepatoma HepG2. J Biomed Sci. 2008;15:343–355
  46. Barker N, Clevers H. Tumor environment: a potent driving force in colorectal cancer?. Trends Mol Med. 2001;7:535–537
  47. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart AL, et al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci. 2001;98:10356–10361
  48. Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Rodrigues M, Diéras V, Mignot L, et al. Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse. Clin Exp Metastasis. 2008;25:871–875
  49. Wrage M, Rousaari S, Eijk PP, Kaifi JT, Hollmén J, Yekebas EF, et al. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res. 2009;15:1566–1574

PII: S0022-5223(10)00573-8

doi: 10.1016/j.jtcvs.2010.02.061

The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 3 , Pages 505-513 , September 2010

Article Tools

* Image Usage & Resolution